HONG KONG – Rigel Pharmaceuticals Inc. has joined forces with Japan's Kissei Pharmaceutical Co. Ltd. to develop and commercialize Rigel's small molecule inhibitor, Tavalisse (fostamatinib), in Japan, the Chinese mainland, Taiwan and South Korea for all potential indications.